Extended Aldosterone Synthase Inhibition Yields Sustained Remission in Primary Aldosteronism

The NEJM-reported extension study tracked participants originally enrolled in an eight-center US trial of the first-in-class aldosterone synthase inhibitor. After stopping therapy, plasma aldosterone and blood-pressure values were compared with pre-treatment baselines using routine clinical measurements. Nearly one-quarter of participants maintained normal blood pressure without any antihypertensive medication, an outcome previously achievable only by unilateral adrenalectomy. The design was pragmatic rather than randomized, limiting causal inference but consistent with the 2005 mouse genetic-deletion model that predicted disappearance of aldosterone-producing cells after prolonged enzyme blockade.

Primary aldosteronism accounts for 5–10% of hypertension cases worldwide. Conventional mineralocorticoid-receptor antagonists lower blood pressure but do not alter the underlying nodular hyperplasia, committing patients to lifelong therapy. The observed persistence of benefit after finite EASI exposure therefore represents a mechanistic departure from symptom management toward disease modification. Funding ties to Cincor and later acquired entities warrant scrutiny in larger trials to exclude selection bias.

A multicenter phase-3 trial with 200–300 participants and mandatory adrenal-vein sampling endpoints is required to confirm durability beyond two years and to quantify the proportion achieving biochemical cure. Regulatory consideration for a finite-course indication will hinge on demonstration that cardiovascular-event rates decline comparably to surgical cohorts.